Effect of tuberculosis preventive treatment on household contacts of rifampin-resistant tuberculosis patients: A nationwide investigation
Kang-Mo Gu, Sun‐Young Jung, Jae-Eun Lee, Joo-Hyeon Eom, Kyungeun Lee, Yong-Joon Park, Yunhyung Kwon, Youmi Kim, et al. (9 authors)
Abstract
<b>Background:</b> South Korea is an intermediate TB burden country with a high incidence rate of rifampin-resistant TB (RR-TB). The effect of tuberculosis (TB) preventive treatment (TPT) on household contacts (HHC) of RR-TB in an intermediate TB burden country has not been well evaluated. Study Design and Methods: This retrospective cohort study analyzed data of HHC investigations from January 2015 to December 2018 in a linked database of the nationwide TB registry and healthcare administrative database of South Korea. The primary outcome was a risk of active TB in HHCs of RR-TB patients following tuberculosis preventive treatment. <b>Results:</b> Out of 82,783 HHCs with data on drug resistance patterns of the index case, 2,593 (4.6%) were in contact with RR-TB patients. Of these 2,593 RR-TB HHCs, 926 (35.7%) were confirmed to have latent TB infection. Among 926 of LTBI patients, 294 (31.7%) had initiated conventional TPT including isoniazid or rifampin, and 168 (57.1%) had completed it. There was no significant difference in the risk of active TB between the TPT complete group and the LTBI-negative group (aHR, 2.27 [95% CI, 0.58-8.83]). In terms of drug resistance profile concordance, 58.7% of the RR-TB HHCs had a concordant drug resistance pattern with the index cases. <b>Conclusion:</b> TB preventive treatment regimens including isoniazid or rifampin effectively prevent TB in household contacts of RR-TB in an intermediate TB burden country. Nationwide HHC investigation combined with TPT may be an effective strategy in reducing TB transmission in intermittent TB burden countries.
MeSH terms
- Medicine
- Tuberculosis
- Isoniazid
- Retrospective cohort study
- Relative risk
- Rifampicin
- Multi-drug-resistant tuberculosis
- Concordance
- Internal medicine
- Incidence (geometry)
- Drug resistance
- Cohort
- Pediatrics